Baidu
map

Lancet:克罗恩病(Crohn)需要积极进行内镜下肠部分切除

2015-01-01 MedSci译 MedSci原创

大多数患者克罗恩病(Crohn's disease)需要肠切除,但大多数随后将经历疾病复发,需要进一步的手术。这项研究的目的是确定的最优策略,以防止术后复发。最近一项随机对照研究发表在Lancet上。 在这项随机对照试验中,共在澳大利亚和新西兰的17个中心进行患者连续招募。肠切除所有肉眼可见的克罗恩病,用内镜治疗,同时患者接受3个月甲硝唑治疗。患者复发高风险采用巯基嘌呤治疗,如果他们不能耐受硫嘌

大多数患者克罗恩病(Crohn's disease)需要肠切除,但大多数随后将经历疾病复发,需要进一步的手术。这项研究的目的是确定的最优策略,以防止术后复发。最近一项随机对照研究发表在Lancet上。

在这项随机对照试验中,共在澳大利亚和新西兰的17个中心进行患者连续招募。肠部分切除所有肉眼可见的克罗恩病,用内镜治疗,同时患者接受3个月甲硝唑治疗。患者复发高风险采用巯基嘌呤治疗,如果他们不能耐受硫嘌呤则采用阿达木单抗治疗。

患者按2:1随机分配。积极治疗组在6个月内进行结肠镜治疗,而标准治疗组则不采用结肠镜手术治疗,采用标准治疗方案。观察6个月时内窥镜复发(Rutgeerts得分≥i2),患者加用巯基嘌呤,阿达木单抗与巯基嘌呤,或每周的阿达木单抗治疗状况。主要终点是在18个月时内镜复发,。患者和治疗医生都知道病人的研究组和治疗,但在镜下所见中央读数进行盲目的研究组和治疗。该试验在ClinicalTrials.gov注册,编号NCT00989560。

在2009年10月13日和2011年9月28日,174例患者入组,并获得研究药物治疗的至少一次。 122例患者在积极治疗组中,47(39%)进行了立即内镜处理。在18个月时,在积极治疗组,内镜下复发为60例(49%),标准治疗组(对照组)为35例(67%)复发(p=0.03)。

在积极治疗组中,粘膜完全正常为27例(22%),对照标准治疗仅为4例(8%)(p=0.03)。在积极治疗组,那些6个月复发进行紧急处理的47例患者中,18例(38%)在12个月后保持缓解。相反,那些在6个月复发没有紧急处理的患者75例,在12个月时31例(41%)没有任何改善。另外,吸烟(OR=2.4,95%CI 1.2-4.8,P =0.02),以及两个或多个临床风险因素的存在,包括吸烟(OR=2.8,95%CI 1.01-7.7,P =0.05)增加了内镜下复发的危险。两组不良事件发生率相似

这样结果表明,早期结肠镜检查和治疗能够改善复发,比单纯常规药物治疗预防术后克罗恩病复发更好。

原始出处:

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV.Crohn's disease management after intestinal resection: a randomised trial.Lancet. 2014 Dec 23. pii: S0140-6736(14)61908-5. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030234, encodeId=97cb203023458, content=<a href='/topic/show?id=28cb526232' target=_blank style='color:#2F92EE;'>#Crohn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5262, encryptionId=28cb526232, topicName=Crohn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Jun 18 13:06:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827965, encodeId=7f4d182e965a2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 04 23:06:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21175, encodeId=0e84211e53b, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Tue Apr 14 21:22:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857339, encodeId=29ba185e3390f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jun 30 03:06:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13719, encodeId=38f513e198d, content=谁翻译的,根本没说明白,数都对不上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.158.4.57, createdTime=Sat Jan 03 11:17:00 CST 2015, time=2015-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261868, encodeId=19ac1261868ca, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Jan 03 04:06:00 CST 2015, time=2015-01-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030234, encodeId=97cb203023458, content=<a href='/topic/show?id=28cb526232' target=_blank style='color:#2F92EE;'>#Crohn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5262, encryptionId=28cb526232, topicName=Crohn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Jun 18 13:06:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827965, encodeId=7f4d182e965a2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 04 23:06:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21175, encodeId=0e84211e53b, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Tue Apr 14 21:22:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857339, encodeId=29ba185e3390f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jun 30 03:06:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13719, encodeId=38f513e198d, content=谁翻译的,根本没说明白,数都对不上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.158.4.57, createdTime=Sat Jan 03 11:17:00 CST 2015, time=2015-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261868, encodeId=19ac1261868ca, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Jan 03 04:06:00 CST 2015, time=2015-01-03, status=1, ipAttribution=)]
    2015-05-04 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030234, encodeId=97cb203023458, content=<a href='/topic/show?id=28cb526232' target=_blank style='color:#2F92EE;'>#Crohn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5262, encryptionId=28cb526232, topicName=Crohn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Jun 18 13:06:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827965, encodeId=7f4d182e965a2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 04 23:06:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21175, encodeId=0e84211e53b, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Tue Apr 14 21:22:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857339, encodeId=29ba185e3390f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jun 30 03:06:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13719, encodeId=38f513e198d, content=谁翻译的,根本没说明白,数都对不上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.158.4.57, createdTime=Sat Jan 03 11:17:00 CST 2015, time=2015-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261868, encodeId=19ac1261868ca, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Jan 03 04:06:00 CST 2015, time=2015-01-03, status=1, ipAttribution=)]
    2015-04-14 Handyuan

    好的

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2030234, encodeId=97cb203023458, content=<a href='/topic/show?id=28cb526232' target=_blank style='color:#2F92EE;'>#Crohn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5262, encryptionId=28cb526232, topicName=Crohn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Jun 18 13:06:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827965, encodeId=7f4d182e965a2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 04 23:06:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21175, encodeId=0e84211e53b, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Tue Apr 14 21:22:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857339, encodeId=29ba185e3390f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jun 30 03:06:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13719, encodeId=38f513e198d, content=谁翻译的,根本没说明白,数都对不上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.158.4.57, createdTime=Sat Jan 03 11:17:00 CST 2015, time=2015-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261868, encodeId=19ac1261868ca, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Jan 03 04:06:00 CST 2015, time=2015-01-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2030234, encodeId=97cb203023458, content=<a href='/topic/show?id=28cb526232' target=_blank style='color:#2F92EE;'>#Crohn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5262, encryptionId=28cb526232, topicName=Crohn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Jun 18 13:06:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827965, encodeId=7f4d182e965a2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 04 23:06:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21175, encodeId=0e84211e53b, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Tue Apr 14 21:22:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857339, encodeId=29ba185e3390f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jun 30 03:06:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13719, encodeId=38f513e198d, content=谁翻译的,根本没说明白,数都对不上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.158.4.57, createdTime=Sat Jan 03 11:17:00 CST 2015, time=2015-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261868, encodeId=19ac1261868ca, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Jan 03 04:06:00 CST 2015, time=2015-01-03, status=1, ipAttribution=)]
    2015-01-03 61.158.4.57

    谁翻译的,根本没说明白,数都对不上!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2030234, encodeId=97cb203023458, content=<a href='/topic/show?id=28cb526232' target=_blank style='color:#2F92EE;'>#Crohn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5262, encryptionId=28cb526232, topicName=Crohn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Thu Jun 18 13:06:00 CST 2015, time=2015-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827965, encodeId=7f4d182e965a2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 04 23:06:00 CST 2015, time=2015-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21175, encodeId=0e84211e53b, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Tue Apr 14 21:22:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857339, encodeId=29ba185e3390f, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Jun 30 03:06:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13719, encodeId=38f513e198d, content=谁翻译的,根本没说明白,数都对不上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=61.158.4.57, createdTime=Sat Jan 03 11:17:00 CST 2015, time=2015-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261868, encodeId=19ac1261868ca, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Jan 03 04:06:00 CST 2015, time=2015-01-03, status=1, ipAttribution=)]

相关资讯

Gut:英夫利昔单抗抗体可增加克罗恩病活动性

尽管低的英夫利昔单抗(infliximab,IFX)波谷浓度及其抗体 (ATI) 与克罗恩病患者差的临床效果密切相关,但英夫利昔单抗抗体与患者体内充足的英夫利昔单抗浓度及其与疾病之间的相互关系尚不明确。比利时鲁汶大学和加拿大西安大略大学的研究者进行了一项研究,发现英夫利昔单抗抗体可增加克罗恩病的活动性,相关研究成果在线发表在近期的Gut杂志上。

Gut:早发型克罗恩病相关新突变位点被发现

IBD是一组由免疫介导的疾病,其主要特征是慢性复发的肠道炎症和各种各样的肠外表现。IBD肠内外的炎症可能和遗传与环境因素相关,但未能完全解释清楚。随着新一代测序工具的发展,遗传因素的研究成为热点。 来自德国石勒苏益格-荷尔斯泰因州大学医疗中心的Sebastian等进行了一项研究,结果表明CTLA4的变异可能是早发型克罗恩病伴严重自身免疫疾病的孟德尔遗传型的基础,文章发表在2014年11月

Liver Int:临床综述:克罗恩病面面观

克罗恩病是一种可累及胃肠道任何部位的慢性、炎性、免疫性疾病,患者涉及所有年龄段,以青年人为高发人群,通常表现为腹泻、腹痛及体重减轻,严重影响患者的工作及生活。多方面的护理,尤其是初级护理,可减少复发,防止长期并发症并提高生活质量。 英国爱丁堡西方总医院遗传和分子医学研究所分子医学中心胃肠病学组的Ian D R Arnott学者及其同事对克罗恩病的诊断、治疗及长期护理等事项进行了归纳总

Lancet:预防克罗恩病肠切除术后复发的更优化策略

大部分克罗恩病(Crohn's disease)患者需要行肠切除,但之后大多数病人会经历疾病复发和需要进一步的手术治疗。近日,澳大利亚圣文森特医院和墨尔本大学医学院等处的研究者进行了一项随机试验,发现根据临床复发风险及早期结肠镜检查和复发早期加强治疗等情况制定的最优化策略可有效预防疾病术后复发,最新研究成果在线发表于12月23日的The Lancet杂志上。

挂线引流术联合药物治疗克罗恩病合并肛瘘的疗效比较

为了比较挂线引流术联合抗TNF-α单抗和联合免疫抑制剂治疗克罗恩病合并肛瘘的临床疗效,中山大学附属第六医院回顾性分析2007年6月至2014年2月医院收治的37例克罗恩病合并肛瘘患者的临床资料。17例患者行挂线引流术联合抗TNFα单抗治疗(抗TNF-α单抗组),20例患者行挂线引流术联合免疫抑制剂治疗(免疫抑制剂组)。比较两组患者瘘口愈合比例、瘘口未愈合比例、肛瘘复发比例、肛瘘复发后再次手术比例

Baidu
map
Baidu
map
Baidu
map